**ASX Announcement**

**Invion Limited (ASX Code IVX)**

**Change of Registered Office and Principal Place of Business**

**7 August 2020**

Invion Limited (**Company**) (**ASX: IVX)** wishes to advise that effective from 14 August 2020, the Company's registered office and telephone number will change to the following:

Level 4
96-100 Albert Road
South Melbourne VIC 3205

Phone: +61 3 9692 7222
Fax: +61 3 9077 9233

The principal place of business has been changed as follows:

692 High Street
East Kew VIC 3102

**For and on Behalf of the Board of Directors and for further information, please contact:**

Melanie Leydin
Company Secretary
+61 3 9692 7222

**Investor enquiries**
Managing Director & CEO, Craig Newton
E: investor@inviongroup.com

**About Invion**
Invion is a life-science company that is leading the global research and development of PhotosoftTM technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the PhotosoftTM technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX). This announcement was approved for release by Craig Newton, MD & CEO. For further information please contact investor@inviongroup.com.

**About Photodynamic Therapy (PDT)**

Invion is developing PhotosoftTM technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.